Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–332 of 332 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 4 mL Injection of Placebo Clear all

Conditions: Healthy
Interventions: Liposomal Bupivacaine 13.3, Bupivacaine, Placebo; Drug · Other
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Moderate to Severe Palmoplantar Psoriasis
Interventions: secukinumab 150 mg, secukinumab 300 mg, Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: Birmingham, Alabama • Phoenix, Arizona • Indianapolis, Indiana + 5 more

Conditions: Staphylococcal Infections
Interventions: SA4Ag vaccine low dose, Blood draw, Colonization swab sample, SA4Ag vaccine mid dose, SA4Ag vaccine high dose, SA3Ag vaccine, Blood sample, Placebo, Colonization swab samples; Biological · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 284 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Hollywood, Florida • South Miami, Florida • Overland Park, Kansas + 4 more

Conditions: Raynaud's Disease
Interventions: onabotulinum toxin type-A; Drug
Lead sponsor: Southern Illinois University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Nasal Polyposis
Interventions: Benralizumab 30 mg SC + Mometasone Furoate, Matching placebo SC + Mometasone Furoate; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 48
States / cities: Birmingham, Alabama • Fresno, California • Huntington Beach, California + 37 more

Conditions: Acute ST Segment Elevation Myocardial Infarction
Interventions: RPH-104 80 mg, Placebo; Biological · Drug
Lead sponsor: R-Pharm Overseas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Cleveland, Ohio • Charlottesville, Virginia • Richmond, Virginia

Conditions: Psoriasis
Interventions: Guselkumab 100 mg, Placebo for guselkumab, Adalimumab, Placebo for adalimumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 837 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 26
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 23 more

Conditions: Chemotherapy-induced Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
Interventions: Tetrodotoxin, Placebo; Drug
Lead sponsor: Wex Pharmaceuticals Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 15
States / cities: Santa Ana, California • Santa Rosa, California • Port Charlotte, Florida + 11 more

Conditions: Obesity
Interventions: Behavioral Treatment, Placebo, Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]; Behavioral · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Relapsing Multiple Sclerosis
Interventions: BIIB017 (peginterferon beta-1a), Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 12
States / cities: Phoenix, Arizona • Ponte Vedra Beach, Florida • Atlanta, Georgia + 9 more

Conditions: Herpes Genitalis
Interventions: VCL-HB01, Phosphate-buffered saline; Biological · Other
Lead sponsor: Vical; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 261 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Birmingham, Alabama • San Diego, California • Hollywood, Florida + 12 more

Conditions: Dengue
Interventions: ISLA101, Dengue 1 Live Virus Human Challenge (DENV-1-LVHC), Placebo; Drug · Other
Lead sponsor: Island Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: East Syracuse, New York

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: naloxone versus placebo, intravenous injection of normal saline or naloxone; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 50 Years to 90 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Allergic Asthma
Interventions: Omalizumab, Placebo, Asthma therapies; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 17 Years to 70 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 100
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Bakersfield, California + 87 more

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: 0.5 mL Candin®/injection, Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline); Biological · Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 6
States / cities: Fayetteville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 3 more

Conditions: Chronic Urticaria
Interventions: TEV-45779, XOLAIR® Injection; Combination Product
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 9
States / cities: Bakersfield, California • Clearwater, Florida • Coral Gables, Florida + 6 more

Conditions: Asthma, Elevated Blood Eosinophils, Oral Corticosteroid Dependence
Interventions: Reslizumab, Placebo, Non-Oral Corticosteroid (non-OCS) Asthma Medication, Oral Corticosteroid (OCS); Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 26
States / cities: Bakersfield, California • Long Beach, California • Clermont, Florida + 21 more

Conditions: Erectile Dysfunction
Interventions: Shock Wave therapy (SWT), Platelet Rich Plasma (PRP), Sham SWT, Placebo Saline; Device · Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 30 Years to 80 Years · Male only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infections
Interventions: DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine, DNA vaccine placebo, HIV-1 recombinant adenovirus vaccine placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 2,504 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2017
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more

Conditions: HIV Infections
Interventions: Cabotegravir Oral Tablet, TDF/FTC tablets, Placebo for TDF/FTC tablets, Placebo for cabotegravir oral tablet, CAB LA, Placebo for CAB LA; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 4,570 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2025
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more

Search by objective public record fields.

Phase 1, Dose Escalation Study to Evaluate of Safety, Pharmacokinetics and Pharmacodynamics of Liposomal Bupivacaine 13.3 Administered Via a Single Intrathecal Injection to Healthy Volunteers

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis

Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years

A Two-Part Study of BOTOX® Therapy for Ischemic Digits

Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis

Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain

Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects

Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

Study to Examine the Effects of Oral Fenretinide

Role of Endorphins in the Perception of Dyspnea in Patients With Chronic Obstructive Pulmonary Disease

A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy

Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils

Shockwave Therapy and Platelet Rich Plasma for the Treatment of Erectile Dysfunction

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men